1 minute reading time (39 words)

Assessment of the FDA Risk Evaluation and Mitigation Strategy for Transmucosal Immediate-Release Fentanyl Products

 Did the US Food and Drug Administration's (FDA's) Transmucosal Immediate-Release Fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS) meet its goal of preventing inappropriate use of TIRF products, such as prescribing to patients without opioid tolerance? Read the abstract.

Related Posts

The AAPM Annual Meeting offers education and networking opportunities for all members of the pain care team.

Learn More